Common Malaria Treatments
Malaria is a mosquito-borne parasitic disease that causes high fever, severe chills, and sweating.
December 1, 2023
by David Orchard-Webb
Vaccinating against Malaria in Africa
Vaccinating against malaria is gaining traction among many countries in malaria-prone Africa region where four-year pilot scheme of administering a malaria vaccine on children has borne good results according to World Health Organization.
August 15, 2023
by SHEM OIRERE
Zydus receives Orphan Drug Designation from US FDA for malaria treatment
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US.
December 17, 2021
by expresspharma
GSK to provide malaria vaccines for Gavi eligible countries
The new development will arm healthcare providers with a vital tool to address the steep rise of malaria cases in children living in Africa.
December 6, 2021
by PharmaTimes
GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children
GlaxoSmithKline (GSK) plc today welcomed the decision of the Gavi Board to provide funding for the procurement and introduction of malaria vaccines into routine child immunisation programmes in Gavi eligible countries.
December 3, 2021
by FirstWordPharma
Monoclonal antibody prevents malaria in small NIH trial
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
August 13, 2021
by europeanpharmaceuticalreview
BioNTech Update on Sustainable Solutions to Infectious Disease in Africa
BioNTech SE announced the launch of its Malaria project, which aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.
July 28, 2021
by americanpharmaceuticalreview
Modus Therapeutics partners with Imperial College London on malaria drug
Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria.
June 16, 2021
by pharmatimes
Sanaria® PfSPZ-CVac vaccine 75 percent effective at preventing malaria
Clinical studies optimising immunisation with Sanaria’s PfSPZ-CVac vaccine resulted in 77 and 75 percent of participants being protected from malaria infection.
June 11, 2021
by europeanpharmaceuticalreview
Novartis announces delivery of one billion courses of anti-malarial treatment
Along with malaria prevention tools and better diagnostics, ACTs remain a key component of the global drive to reach malaria elimination.
May 21, 2021
by expresspharma
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.
May 20, 2021
by worldpharmanews
Novel vaccination regimen shown to be effective in preventing malaria
A three-dose regimen of Plasmodium falciparum sporozoites under chemoprophylaxis (PfSPZ-CVac) was shown to be safe, well tolerated and highly effective in a Phase II trial.
May 7, 2021
by europeanpharmaceuticalreview